Dr Ian Tomlinson

Ian Tomlinson M.A. (Cantab) Ph.D.

Ian Tomlinson has over 30 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. He co-founded Domantis Limited with Nobel Laureate Sir Gregory Winter, which was acquired by GSK for $454 million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK, where he led an ambitious strategy to grow GSK's pipeline of clinical stage biopharmaceuticals from under 10% in 2008 to over 50% by 2016.

Following his departure from GSK, he chaired the Stevenage Bioscience Catalyst, the UK's first open innovation biomedical campus and is currently Founding Director and SAB Chair for Apollo Therapeutics, a unique venture dedicated to turning academic science into cutting edge medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge. He also chairs Start Codon, the first life sciences accelerator based in Cambridge, UK, which aims to nurture vibrant new lifesciences companies that are built to succeed globally.

Dr Tomlinson graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.